Spiegelin jutusta:.
Melkoista mikäli totta. Saatiin hienosti politisoitua rokotehankinnat, ja lopputuloksena kaikki häviävät. Sanofin rokotteessahan meni joku vituiksi ja valmista pitäis olla joskus vuoden päästä.
www.spiegel.de
The EU only secured 200 million doses from BioNTech, with an option for 100 million more that would be manufactured later. According to sources with knowledge of the negotiations, BioNTech had additional capacity and apparently offered that capacity to the EU: up to 500 million doses in the first round.
But the European Commission reportedly rejected the offer. European Health Commissioner Stella Kyriakides would not comment on the exact reason. "We do not comment on the progress of negotiations," a commission spokesman said.
Why were only 300 million doses of a vaccine secured that had already demonstrated 95 percent efficacy in clinical trials at the time? One that had been hailed as a sensation and was already on its way to regulatory approval? German Health Minister Spahn pushed for more to be purchased, but he failed to prevail in the end due to opposition from several EU member countries -- in part, apparently, because the EU had ordered only 300 million doses from the French company Sanofi. "That’s why buying more from a German company wasn't in the cards,” says one insider familiar with the negotiations. The European Commission has denied that version of events, saying it isn’t true that Paris took massive steps to protect Sanofi.
Melkoista mikäli totta. Saatiin hienosti politisoitua rokotehankinnat, ja lopputuloksena kaikki häviävät. Sanofin rokotteessahan meni joku vituiksi ja valmista pitäis olla joskus vuoden päästä.
Corona: Germany and Europe Could Fall Short on Vaccine Supplies
The EU and Berlin have insisted there will be sufficient vaccine available, but delays in signing purchasing contracts mean that the elixir will arrive late and there might not be enough. The EU even declined an option that would have allowed for the purchase of hundreds of millions of extra doses.